Mysimba Review

Mysimba is a new anti-obesity drug that can appear at the European market of weight loss products in 2015. Summary of product characteristics (SmPC) for Mysimba is not yet published, but it is already known that this drug will be prescribed to patients with BMI of 27 and above for weight loss.

The developer of new Mysimba diet pills is Orexigen Therapeutics. It is planned that the marketing authorization for Mysimba in the Europe will be granted to Orexigen Therapeutics Ireland Limited.

The results of clinical studies have demonstrated that Mysimba diet pills provide a significant weight reduction. Herewith, Committee for Medicinal Products for Human Use (CHMP) confirmed that the benefits of new Mysimba diet pills exceed their potential risks to the health of overweight and obese patients.

In December 2014, the European Medicines Agency published the information that active ingredients included in Mysimba pills affect eating behavior, help to control calorie diet and to reduce the frequency of food intake.

When manufacturing Mysimba pills, two active ingredients included in different pharmacological groups, are used.

  • Naltrexone – is an opioid receptor antagonist
  • Bupropion – is an atypical antidepressant

Drugs containing just one of these pharmaceutical substances are already available at the European pharmaceutical market.

  • Active ingredient Naltrexone is included in oral drugs for the treatment of opioid or alcohol dependence. At the UK pharmacies, Naltrexone-containing drugs are sold under the trademarks Adepend and Nalorex.
  • Active ingredient Bupropion is included in oral drugs for the treatment of major depressive disorder and nicotine addiction. Only Zyban – Bupropion-containing stop smoking pills are available at the UK market.

Each of the active ingredients Mysimba pills is used for the production of oral drugs for more than 30 years. Therefore,mysiba their pharmacological properties and potential side effects are well- studied.

The combination of active ingredients Bupropion and Naltrexone was studied only in the development of Mysimba diet pills. Data of pre-clinical and clinical studies demonstrates that the most common side effects of the fixed doses of Bupropion 90mg and Naltrexone 8mg include: dry mouth, dizziness, nausea, vomiting, and constipation.

When the dosing regimen of Mysimba is observed, these side effects do not occur or weakly expressed. Therefore, obese patients taking Mysimba diet pills do not cause harm to their health and do not experience a serious discomfort.

It should be noted that diet pills containing Bupropion and Naltrexone are sold in the USA already several months. At the U.S. market, these diet pills are available under the alternative trade name Contrave.

In late 2014, Orexigen Therapeutics announced the start of Contrave sale. The marketing authorization for Contrave is granted to the main U.S. partner of Orexigen – Takeda Pharmaceutical Company Limited (Takeda).

Summary of product characteristics (SmPC) for Contrave has already been published, but detailed information about Mysimba is not yet available. Today, we can confidently assert that Contrave and Mysimba drugs contain the same active ingredients and indications for their use are identical.

It is possible that Mysimba pills that will be sold in the Europe will be different from Contrave pills already available at the US market. Very often, absolutely identical diet pills, manufactured by the same pharmaceutical company differ not only by the trademark, but also the shape, color, type and size of pack, as well as price.

After the SmPC publication for Mysimba, the differences and similarities of Contrave and Mysimba diet pills can be compared. After Mysimba pills will come into the market, it will be possible to compare their price with the price of Contrave and other diet pills available at the international market. The latest and the most relevant information about Mysimba and other anorexigenic diet pills can be found in the following reviews.

Leave a Reply

Your email address will not be published. Required fields are marked *

*